Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Grant
Filed:
August 25, 2020
Date of Patent:
June 14, 2022
Assignee:
GenVec, Inc.
Inventors:
Douglas E. Brough, Jason G. D. Gall, Duncan McVey
Abstract: The invention is directed to a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a human atonal homolog-1 (Hath1) protein operably linked to a human glial fibrillary acidic protein (GFAP) promoter. The invention also is directed to a composition and method utilizing the adenoviral vector to generate sensory cells in the inner ear of a human.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
March 22, 2022
Assignee:
GenVec, Inc.
Inventors:
Douglas E. Brough, Damodar R. Ettyreddy
Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.
Type:
Application
Filed:
March 12, 2021
Publication date:
September 2, 2021
Applicant:
GenVec, Inc.
Inventors:
Lisa Wei, Douglas E. Brough, C. Richter King
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexone protein, and/or fiber protein.
Type:
Grant
Filed:
February 22, 2019
Date of Patent:
June 15, 2021
Assignee:
GenVec, Inc.
Inventors:
Jason G. D. Gall, Duncan McVey, Douglas E. Brough
Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
March 16, 2021
Assignee:
GenVec, Inc.
Inventors:
Lisa Wei, Douglas E. Brough, C. Richter King
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Application
Filed:
August 25, 2020
Publication date:
February 11, 2021
Applicant:
GenVec, Inc.
Inventors:
Douglas E. Brough, Jason G.D. Gall, Duncan McVey
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
October 6, 2020
Assignee:
GenVec, Inc.
Inventors:
Duncan McVey, Douglas E. Brough, Jason G. D. Gall
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
September 29, 2020
Assignee:
GenVec, Inc.
Inventors:
Douglas E. Brough, Jason G. D. Gall, Duncan McVey
Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
September 22, 2020
Assignee:
GenVec, Inc.
Inventors:
Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.
Type:
Grant
Filed:
September 7, 2017
Date of Patent:
May 5, 2020
Assignee:
GenVec, Inc.
Inventors:
Jason G. D. Gall, Douglas E. Brough, C. Richter King
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Application
Filed:
February 22, 2019
Publication date:
October 17, 2019
Applicant:
GenVec, Inc.
Inventors:
Jason G.D. Gall, Duncan McVey, Douglas E. Brough
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Application
Filed:
March 13, 2019
Publication date:
September 5, 2019
Applicant:
GenVec, Inc.
Inventors:
Duncan McVey, Douglas E. Brough, Jason G.D. Gall
Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
Type:
Application
Filed:
April 24, 2019
Publication date:
August 15, 2019
Applicant:
GenVec, Inc.
Inventors:
Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
June 11, 2019
Assignee:
GenVec, Inc.
Inventors:
Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
April 30, 2019
Assignee:
GenVec, Inc.
Inventors:
Duncan McVey, Douglas E. Brough, Jason G. D. Gall
Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
April 16, 2019
Assignee:
GenVec, Inc.
Inventors:
Jason G. D. Gall, Duncan McVey, Douglas E. Brough
Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
Type:
Application
Filed:
October 10, 2018
Publication date:
April 4, 2019
Applicant:
GenVec, Inc.
Inventors:
Lisa Wei, Douglas E. Brough, Christopher Lazarski